Pacira BioSciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pacira BioSciences, Inc.
Reviving A Longsuffering Neuro Company: The Marinus Story
Marinus Pharmaceuticals’ CEO spoke candidly to In Vivo about breathing new life into ultra-rare epilepsy disorder drug ganaxolone.
Finance Watch: VC Mega-Rounds Are Alive And Well
Private Company Edition: Also, Catalio closed a $381m venture capital fund and OrbiMed’s SEC filings indicate it is in the process of raising $4.75bn across three new funds. Dianthus launched with $100m and Tubulis closed a $63m series B round.
Axsome Is Latest To Falter With Technology For Unlocking Meloxicam’s Analgesic Potential
Axsome’s CRL was not the first from the US FDA for the nearly insoluble NSAID as sponsors try different technologies for delivering its pain relief quickly.
Pacira Aims For Non-Opioid Pipeline Growth With Flexion Buy
Flexion’s Zilretta is forecast to have big market potential with the growth of osteoarthritis, and Pacira’s CEO suggested there were commercial synergies with its Iovera device.
- Specialty Pharmaceuticals
- Controlled Release
- Surgical Equipment & Devices
- Other Names / Subsidiaries
- Blue Acquisition Corp.
- DepoTech Corp.
- Flexion Therapeutics, Inc.
- myoscience, Inc.
- Pacira CryoTech, Inc.
- Pacira Pharmaceuticals, Inc.
- SkyePharma Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.